Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:acetylcholinesterase_inhibitor carbamate |
| gptkbp:approvalYear |
1997
|
| gptkbp:ATCCode |
gptkb:N06DA03
|
| gptkbp:brand |
gptkb:Exelon
Prometax |
| gptkbp:CASNumber |
gptkb:123441-03-2
|
| gptkbp:discoveredBy |
gptkb:Novartis
|
| gptkbp:eliminationHalfLife |
1.5 hours (oral)
3 hours (patch) |
| gptkbp:hasMolecularFormula |
C14H22N2O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rivastigminum
|
| gptkbp:KEGGID |
D08445
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits acetylcholinesterase and butyrylcholinesterase
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201197
77991 70341 DB00989 |
| gptkbp:routeOfAdministration |
oral
transdermal patch |
| gptkbp:sideEffect |
nausea
vomiting diarrhea dizziness headache loss of appetite |
| gptkbp:synonym |
gptkb:rivastigmine
|
| gptkbp:UNII |
K9U2F0V3BW
|
| gptkbp:usedFor |
gptkb:Alzheimer's_disease
gptkb:Parkinson's_disease_dementia |
| gptkbp:bfsParent |
gptkb:rivastigmine
|
| gptkbp:bfsLayer |
8
|